Announcements
Trials
Browse
Landscape
Eligibility
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
pembrolizumab
×
Other hematologic neoplasm
×
Clear all
Filters
3
NCT03486873
2026-03-16
MK-3475-587
Merck Sharp & Dohme LLC
Phase 3
Recruiting
3,500 enrolled